| abstract |
The present invention relates to therapeutically active heterocyclic compounds of formula (I) wherein n is 0, 1 or 2; and X is -O-, -S, -N(R5)- or -CH¿2?-; and R?1¿ is H, NH¿2, NHR?5 or OH; and R?2 and R3¿ independently are H, COOH, COOR5, CONH¿2?, CONHR?5, CON(R5)¿2, CONHSO2R5 or tetrazole; and R4 is H, OH, NH¿2?, NHR?5, CF¿3, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C3-6-cycloalkyl, phenyl or C1-4-alkoxy; and R5 is H, C¿1-8?-alkyl, C2-8-alkenyl, C2-8-alkynyl, phenyl or C3-6-cycloalkyl; and ring A can be partly or completely saturated or aromatic, or a salt thereof with a pharmaceutically acceptable acid or base, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to the metabotropic glutamate receptor system. |